Amide-Linked EP4 Agonist Conjugates for Targeted Bone Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing EP4 agonists are associated with systemic side effects, and there is a need for targeted delivery of EP4 agonists to specific sites like bone to treat conditions related to abnormal bone loss or resorption without these side effects.
Innovation Solution
Development of EP4 agonist-bisphosphonate conjugate compounds linked via an amide linker, where the EP4 agonist is connected to the bisphosphonate through an ester bond and an amide bond, allowing selective delivery and binding to bone, with potential hydrolysis to release the active agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EP4 agonists are administered systemically to treat bone conditions, then therapeutic effect on bone is achieved, but systemic side effects occur
Solution Approach 1:
The patent applies local quality by creating a conjugate compound where the EP4 agonist is selectively delivered to bone tissue through linkage to a bone-targeting moiety. This ensures the therapeutic agent acts locally at the bone site rather than systemically, thereby achieving therapeutic effect while minimizing systemic side effects.
Solution Approach 2:
The patent uses an intermediary approach by introducing a conjugate structure that links the EP4 agonist to a bone-targeting moiety. This intermediary conjugate enables selective delivery of the agonist to bone tissue, acting as a mediator between systemic administration and localized action, thus reducing systemic exposure while maintaining therapeutic efficacy.
2Reliability
If EP4 agonist-bisphosphonate conjugate compounds are developed for targeted delivery, then selective delivery to bone is achieved, but compound complexity increases
Solution Approach 1:
The patent applies composite materials by creating a conjugate compound that combines an EP4 agonist with a bone-targeting moiety (such as a bisphosphonate). This composite structure integrates the therapeutic function of the agonist with the targeting function of the bisphosphonate, enabling selective delivery to bone tissue while managing the complexity through rational molecular design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate compounds provide efficient uptake and targeted delivery of EP4 agonists to bone, minimizing systemic side effects and effectively treating conditions such as osteoporosis and bone fractures by releasing the active agent at the site of action.
Implementation Method 1
the EP4 agonist is connected to the bisphosphonate through an ester bond and an amide bond
Implementation Method 2
the EP4 agonist is connected to the bisphosphonate through an ester bond and an amide bond
Implementation Method 3
with potential hydrolysis to release the active agent
Data Source
AI summary
The present invention relates to conjugate compounds and methods of making and using same.